A novel treatment for relapsed/refractory B-cell malignancies has received investigational new drug (IND) clearance from the US Food and Drug Administration (FDA).  APG-3288, developed by biopharmaceutical company Ascentage Pharma, is a novel next-generation BTK-targeted protein degrader. The candidate is designed to induce rapid, potent, highly selective, and sustained degradation of both wild-type BTK and multiple BTK mutants associated […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!